Koss Olinger Consulting, LLC Bristol Myers Squibb CO Transaction History

Koss Olinger Consulting, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 10, 2023	BUY	$57.89 - $64.73 $173 - $194	3 Added 0.08%	3,595 $208,000
Q2 2023 Jul 28, 2023	SELL	$63.71 - $70.74 $44,851 - $49,800	-704 Reduced 16.39%	3,592 $229,000
Q1 2023 May 12, 2023	SELL	$65.71 - $74.53 $42,317 - $47,997	-644 Reduced 13.04%	4,296 $297,000
Q4 2022 Feb 13, 2023	BUY	$68.48 - $81.09 $92,995 - $110,120	1,358 Added 37.91%	4,940 $355,000
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $24 - $14,522	-189 Reduced 5.01%	3,582 $255,000
Q2 2022 Jul 08, 2022	BUY	$72.62 - $79.98 $363 - $399	5 Added 0.13%	3,771 $290,000
Q1 2022 May 06, 2022	BUY	$61.48 - $73.72 $26,743 - $32,068	435 Added 13.06%	3,766 $275,000
Q4 2021 Feb 07, 2022	SELL	$53.63 - $62.52 $362,699 - $422,822	-6,763 Reduced 67.0%	3,331 $208,000
Q3 2021 Nov 09, 2021	SELL	$59.17 - $69.31 $289,459 - $339,064	-4,892 Reduced 32.64%	10,094 $597,000
Q2 2021 Aug 11, 2021	BUY	$61.91 - $67.42 $65,748 - $71,600	1,062 Added 7.63%	14,986 $1 Million
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $826,250 - $929,287	13,924 New	13,924 $879,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Koss Olinger Consulting, LLC, based on Form 13F filings with the SEC.

Stay updated on Koss Olinger Consulting, LLC with notifications on news.